AI Summary
We reviewed 10000 live results for kiovig 100mg/ml solution for infusion and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biologics and Prescription Only Medicine.
Comparison Table
Source: Takeda
Description
Kiovig is a 10% solution (100 mg/mL) of human normal immunoglobulin (IVIg) for intravenous or subcutaneous administration. It is used as replacement therapy for patients with primary immunodeficiency (PID) and secondary immunodeficiency (SID). Additionally, it acts as an immunomodulatory therapy for conditions such as immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, Kawasaki disease, Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The product is available in various vial sizes, including 1g, 2.5g, 5g, 10g, 20g, and 30g concentrations.
Best for
primary immunodeficiency replacement, CIDP and MMN treatment, Kawasaki disease management, intravenous immunoglobulin therapy and subcutaneous infusion preference
Rating
Source: AstraZeneca Malaysia
Description
Locally registered and approved formulation of Soliris available in Malaysia. This concentrate is intended for intravenous infusion in clinical settings for the treatment of rare conditions such as aHUS and PNH. It is regulated as a scheduled poison by the Malaysian National Pharmaceutical Regulatory Agency (NPRA).
Best for
Malaysian residents, hospital-based infusion, NPRA-approved prescriptions and local rare disease support
Rating
Source: Celltrion, Inc.
Description
Truxima is a monoclonal antibody and biosimilar to the reference product MabThera (rituximab). It is used as a targeted cancer therapy for Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), as well as for treating Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is available in 100mg/10ml and 500mg/50ml single-dose vials for intravenous infusion.
Best for
Oncology patients, Rheumatoid arthritis treatment, Biosimilar cost-savings and Targeted immunotherapy
Rating
| Compare | Kiovig 100mg/mL Solution for Infusion | Soliris 10mg/ml Concentrate for Solution for Infusion | Truxima 10mg/ml Concentrate for Solution for Infusion |
|---|---|---|---|
| Source | Takeda | AstraZeneca Malaysia | Celltrion, Inc. |
| Description | Kiovig is a 10% solution (100 mg/mL) of human normal immunoglobulin (IVIg) for intravenous or subcutaneous administration. It is used as replacement therapy for patients with primary immunodeficiency (PID) and secondary immunodeficiency (SID). Additionally, it acts as an immunomodulatory therapy for conditions such as immune thrombocytopenic purpura (ITP), Guillain-Barré syndrome, Kawasaki disease, Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The product is available in various vial sizes, including 1g, 2.5g, 5g, 10g, 20g, and 30g concentrations. | Locally registered and approved formulation of Soliris available in Malaysia. This concentrate is intended for intravenous infusion in clinical settings for the treatment of rare conditions such as aHUS and PNH. It is regulated as a scheduled poison by the Malaysian National Pharmaceutical Regulatory Agency (NPRA). | Truxima is a monoclonal antibody and biosimilar to the reference product MabThera (rituximab). It is used as a targeted cancer therapy for Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), as well as for treating Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is available in 100mg/10ml and 500mg/50ml single-dose vials for intravenous infusion. |
| Best for | primary immunodeficiency replacement, CIDP and MMN treatment, Kawasaki disease management, intravenous immunoglobulin therapy and subcutaneous infusion preference | Malaysian residents, hospital-based infusion, NPRA-approved prescriptions and local rare disease support | Oncology patients, Rheumatoid arthritis treatment, Biosimilar cost-savings and Targeted immunotherapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Kiovig 100mg/mL Solution for Infusion from Takeda."
I picked this because Kiovig is a versatile, high-concentration immunoglobulin therapy registered with the NPRA in Malaysia, offering flexible dosing options for both immunodeficiency and neuromuscular conditions.
Share this search
Related Finds